Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 21,040 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ONE Clear all

Conditions: Acne
Interventions: BEAM device; Device
Lead sponsor: Oregon Aesthetic Technologies; Industry
Eligibility: 15 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 3
States / cities: Miami Beach, Florida • Warren, Michigan • Portland, Oregon

Conditions: Meningitis, Meningococcal Infection
Interventions: MenACWY-CRM197, DTaP (Diptheria, Tetanus, Pertussis) Vaccine, Hib (Haemophilus influenza b) Vaccine, IPV (Inactivated Polio Vaccine) Vaccine, Pneumococcal conjugate Vaccine, MMR (Measles, Mumps, and Rubella) Vaccine, Varicella Vaccine, Hepatitis A Virus; Biological
Lead sponsor: Novartis; Industry
Eligibility: 55 Days to 89 Days
Enrollment: 7,744 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 130
States / cities: Birmingham, Alabama • Dothan, Alabama • Tuscon, Arizona + 107 more

Conditions: Medium-chain Acyl-CoA Dehydrogenase Deficiency
Interventions: Sodium phenylbutyrate; Drug
Lead sponsor: Jerry Vockley, MD, PhD; Other
Eligibility: 10 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Geographic Atrophy
Interventions: Not listed
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 50 Years and older
Enrollment: 68,563 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Nervous System Disorders
Interventions: Botulinum toxin type A; Biological
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 13
States / cities: Downey, California • Fairfield, Connecticut • Boca Raton, Florida + 9 more

Conditions: Healthy
Interventions: Individualized Print-Based Motivational Program; Behavioral
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 256 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Postoperative Pain, Anxiety Postoperative, Opioid Use
Interventions: Virtual Realty using a Microsoft Hololens, Empatica HR wristband, and EEG, Essence Olfactory Necklace, Bedside Olfaction Device; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: MGMT-unmethylated Glioblastoma (GBM), IDH Wildtype Glioblastoma
Interventions: avutometinib and defactinib for 3 weeks on/1 week off, MGMT-unmethylated GBM with Radiation; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Atlanta, Georgia • Baltimore, Maryland

Conditions: Prostate Cancer
Interventions: Revlimid; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Colorectal Neoplasms
Interventions: Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2032
U.S. locations: 989
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 616 more

Conditions: Physical Disability
Interventions: Heel Cushion Material Bulk (foam); Device
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Menopause
Interventions: Estradiol withdrawal, Fragmented sleep; Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alzheimer Disease, Alzheimer Disease, Late Onset
Interventions: MemorEM 1000; Device
Lead sponsor: NeuroEM Therapeutics, Inc.; Industry
Eligibility: 63 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: HIV Infections
Interventions: Health Access Coalitions, Social Media, Peer Support, Promoting Human Autonomy Support & Empathy (PHASE); Behavioral
Lead sponsor: HIV Prevention Trials Network; Network
Eligibility: 15 Years and older · Male only
Enrollment: 2,700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cancer of Pancreas, Cancer of Pelvis, Cancer of Abdomen, Cancer of Thorax
Interventions: Ring gantry kV-CBCT combined with linear accelerator; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type
Interventions: ATLCAR.CD30 cells; Biological
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 3 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2039
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Advanced Cancer, Anorexia, Weight Loss, Insomnia
Interventions: Mirtazapine, Placebo; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Lower Limb Arterial Occlusion
Interventions: Artix Thrombectomy System; Device
Lead sponsor: Inari Medical; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 23
States / cities: San Francisco, California • New Haven, Connecticut • Washington D.C., District of Columbia + 20 more

Conditions: Periodontitis, Diabetes Mellitus Type 2
Interventions: local antibiotic application of topical minocycline, Scaling and Root Planing; Drug · Procedure
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Critical Limb Ischemia, Malnutrition, Nutritional Supplements
Interventions: Ensure Surgery Immunonutrition Shake, Ensure Enlive Advanced Nutrition Shake; Drug
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Trastuzumab deruxtecan (DS-8201a), Capecitabine, Eribulin, Gemcitabine, Paclitaxel, Nab-paclitaxel; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 557 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 38
States / cities: Chandler, Arizona • Gilbert, Arizona • Goodyear, Arizona + 31 more

Conditions: Anxiety Disorders, Depression, Psychological Distress, Tobacco Dependence, Smoking, Tobacco, Smoking, Cigarette
Interventions: PFI for Smoking & Distress Tolerance, PFI for Smoking Only; Behavioral
Lead sponsor: University of Houston; Other
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Antiphospholipid Syndrome
Interventions: INR by point-of-care instruments and venopuncture; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Tobacco Dependence, Tobacco Smoking
Interventions: Smoke-free home resident intervention, Lay Health Worker coaching; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 544 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Safety & Effectiveness of the BEAM Device in Mild-to-moderate Acne

Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)

Patients With Geographic Atrophy and Their Patient Journey in the United States (US)

Dysport® Adult Upper Limb Spasticity Extension Study

Individualized Motivational Print Materials to Encourage More Physical Activity

Virtual Reality and Olfactory Stimuli Multimodal Intervention to Reduce Post-Operative Pain and Anxiety in Patients Undergoing Cardiothoracic Surgery

Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas

Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer

S0820, Adenoma and Second Primary Prevention Trial

The Influence of Heel Wedge Properties on Roll-over of the Intrepid Dynamic Exoskeletal Orthosis (IDEO)

Menopausal Sleep Fragmentation and Body Fat Gain

Safety and Efficacy of Transcranial Electromagnetic Treatment Against Alzheimer's Disease

Getting to Zero Among HHI MSM in the American South

Daily Imaging, Target Identification, and Simulated Computed Tomography-Based Stereotactic Adaptive Radiotherapy Workflow in a Novel Ring Gantry Radiotherapy Device

Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

Effects of Mirtazapine on Appetite in Advanced Cancer Patients

The ArtixASCEND Study

Effect of Arestin-Enhanced SRP on Periodontal and Glycemic Outcomes in Diabetics

Nutrition in Patient With Critical Limb Ischemia

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Personalized Feedback for Distress Intolerant Smokers

Reliability of Point-of-care INR Measurements in Patients With Antiphospholipid-antibody Syndrome Treated With Warfarin

Smoke-free Home Study in Subsidized Housing